These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3539124)

  • 1. Bactericidal effect of combinations of cephalosporins with tobramycin on clinical isolates of Escherichia coli, Klebsiella and Staphylococcus aureus.
    Wagenvoort JH; Brus-Weijer L; Michel MF
    Arzneimittelforschung; 1986 Sep; 36(9):1301-2. PubMed ID: 3539124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro synergy of cefamandole-tobramycin combinations.
    Valenti AJ; Siniscalchi AJ; Andriole VT
    Yale J Biol Med; 1977; 50(2):177-82. PubMed ID: 331694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal effect of combinations of antibiotic and antineoplastic agents against Staphylococcus aureus and Escherichia coli.
    Nyhlén A; Ljungberg B; Nilsson-Ehle I; Odenholt I
    Chemotherapy; 2002 May; 48(2):71-7. PubMed ID: 12011538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial resistance: patterns and trends in the National University Hospital, Singapore (1989-1991).
    Kumarasinghe G; Liew HY; Chow C
    Malays J Pathol; 1992 Dec; 14(2):95-103. PubMed ID: 1304631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism and postantibiotic effect of tobramycin and Melaleuca alternifolia (tea tree) oil against Staphylococcus aureus and Escherichia coli.
    D'Arrigo M; Ginestra G; Mandalari G; Furneri PM; Bisignano G
    Phytomedicine; 2010 Apr; 17(5):317-22. PubMed ID: 19699074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation in an animal model and in vitro of the combination clavulanic acid and cephalosporins against beta-lactamase producing and nonproducing Staphylococcus aureus strains.
    de Sá Del Fiol F; Rocha De Mattos Filho T; Groppo FC
    Braz J Infect Dis; 2000 Feb; 4(1):36-42. PubMed ID: 10788844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of moxalactam (LY-127935) compared with cefotaxime and other beta-lactam antibiotics against clinical isolates of enterobacteriacea and non-fermenters.
    Verbist L
    Arzneimittelforschung; 1981; 31(6):982-6. PubMed ID: 6266430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Susceptibility of some bacteria isolated from clinical samples to third-generation cephalosporins].
    Willke A; Tural D
    Mikrobiyol Bul; 1987 Oct; 21(4):279-83. PubMed ID: 3332704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Patterns of resistance of Staph aureus and gram-negative bacteria to aminoglycosides and cephalosporins].
    Ruczkowska J; Dolna I
    Wiad Lek; 1989 May; 42(9):579-83. PubMed ID: 2629327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period.
    Hanberger H; Burman LG; Cars O; Erlandsson M; Gill H; Nilsson LE; Nordlinder D; Walther SM;
    Acta Anaesthesiol Scand; 2007 Aug; 51(7):937-41. PubMed ID: 17635399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I
    Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antibacterial activity of a new 1-oxa cephalosporin compound.
    Downs JT; Andriole VT
    Yale J Biol Med; 1980; 53(2):149-59. PubMed ID: 6446810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
    Corser CA; Day GJ; Humble MW
    N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended spectrum b lactamases (ESBL) in clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    Duttaroy B; Mehta S
    Indian J Pathol Microbiol; 2005 Jan; 48(1):45-8. PubMed ID: 16758790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of cefoxitin, a new cephalosporin (author's transl)].
    Shah PM; Zwischenbrugger H; Stille W
    MMW Munch Med Wochenschr; 1976 Nov; 118(45):1469-72. PubMed ID: 825763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro bactericidal action of cephalosporins in different concentrations of serum.
    Magliulo E; Ceccarelli G; Bianchi PP; Piantieri G; Cafarelli A
    G Batteriol Virol Immunol; 1981; 74(1-6):39-47. PubMed ID: 6458527
    [No Abstract]   [Full Text] [Related]  

  • 19. Susceptibility of bacterial isolates to cefepime in comparison to other broad spectrum antimicrobial agents at a tertiary care center in Lebanon.
    Kanj SS; Chedid M; Araj GF
    J Med Liban; 2001; 49(1):13-7. PubMed ID: 11910959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of several antimicrobial agents against selected clinical isolates.
    Liebowitz LD; Saunders J; Chalkley LJ; Koornhof HJ
    S Afr Med J; 1990 Apr; 77(8):395-400. PubMed ID: 2109875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.